Get the Stockscreener App
1.24
1.59%
-0.02
After Hours:
1.24
Actinium Pharmaceuticals Inc stock is traded at $1.24, with a volume of 147.92K.
It is down -1.59% in the last 24 hours and up +13.76% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.26
Open:
$1.3
24h Volume:
147.92K
Relative Volume:
0.86
Market Cap:
$38.90M
Revenue:
$90,000
Net Income/Loss:
$-33.89M
P/E Ratio:
-1.1415
EPS:
-1.0863
Net Cash Flow:
$-24.68M
1W Performance:
+5.98%
1M Performance:
+13.76%
6M Performance:
-6.06%
1Y Performance:
-10.14%
1-Day Range:
$1.2251
$1.30
1-Week Range:
$1.11
$1.30
52-Week Range:
$0.952
$1.9454
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.24 | 39.53M | 90,000 | -33.89M | -24.68M | -1.0863 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - PR Newswire
ATNM Should I Buy - Intellectia AI
Actinium presents preclinical data on AML drug at AACR meeting By Investing.com - Investing.com India
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Fi - GuruFocus
Actinium Pharmaceuticals (ATNM) Presents Promising Data on Actim - GuruFocus
Actinium presents preclinical data on AML drug at AACR meeting - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 By Investing.com - Investing.com South Africa
Dr. Electric Explains What Colorado Springs Homeowners Should Check Before Summer Electrical Demand Peaks - Weekly Voice
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting - PR Newswire
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
MSN Money - MSN
Actinium (ATNM) Stock: Is It a Strong Buy? (+4.00%) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Aug Macro: Is now the right time to enter Actinium Pharmaceuticals Inc2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Actinium Pharma unveils groundbreaking data on radiotherapy platform at AACR 2026 - Indian Pharma Post
Aug Highlights: Can Actinium Pharmaceuticals Inc outperform in the next rallyJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Support Test: Is Actinium Pharmaceuticals Inc subject to activist investor interest2026 Weekly Recap & Target Return Focused Picks - baoquankhu1.vn
ATNM Q4 2025 Earnings: Actinium Pharma misses EPS, reports zero revenueHold Rating - Newser
ATNM Stock Price, Quote & Chart | ACTINIUM PHARMACEUTICALS INC (NYSEARCA:ATNM) - ChartMill
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - The AI Journal
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting – Company AnnouncementFT.com - Financial Times
Actinium to present preclinical data at AACR meeting April 21 - Investing.com
Aug Mood: Can Actinium Pharmaceuticals Inc outperform in the next rallyWeekly Market Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
What is HC Wainwright’s Estimate for ATNM FY2026 Earnings? - Defense World
ATNM Shareholders Have Opportunity to Lead Actinium Pharmaceutica - The National Law Review
Research Analysts Set Expectations for ATNM Q1 Earnings - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Receives “Overweight” Rating from Stephens - Defense World
ATNM: Stephens & Co. Reiterates Overweight Rating with $5.00 Tar - GuruFocus
Actinium Pharmaceuticals 2026 Annual Report: Clinical-Stage Radiopharmaceutical Innovations, Competitive Strengths, and Regulatory Risk Factors - Minichart
Actinium: Q4 Earnings Snapshot - KVUE
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Actinium Pharmaceuticals (NYSE: ATNM) outlines radiotherapy pipeline, losses and 2026 manufacturing plans - Stock Titan
Actinium Pharmaceuticals (ATNM) Eps Diluted (TTM) - Zacks Investment Research
Portfolio Shifts: What is the dividend yield of Actinium Pharmaceuticals Inc2026 Market Overview & Weekly High Return Stock Forecasts - baoquankhu1.vn
Actinium Pharmaceuticals (ATNM) board adopts annual Say-on-Pay advisory votes - Stock Titan
Comparing UCB (OTCMKTS:UCBJF) and Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Fundamentals Check: Is Actinium Pharmaceuticals Inc undervalued by DCF analysis - baoquankhu1.vn
If You Invested $1,000 in Actinium Pharmac (ATNM) - Stock Titan
Stop Loss: What is the next catalyst for Actinium Pharmaceuticals IncCEO Change & Reliable Breakout Forecasts - baoquankhu1.vn
Analysis Recap: Is Actinium Pharmaceuticals Inc stock good for income investors2026 Market Mood & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Wall Street Recap: Is Actinium Pharmaceuticals Inc stock trending bullishInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
IPO Launch: Can Actinium Pharmaceuticals Inc stock double in the next year2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Aug Shorts: What is the dividend yield of Actinium Pharmaceuticals Inc2025 Investor Takeaways & Technical Pattern Alert System - baoquankhu1.vn
Market Rankings: Is Actinium Pharmaceuticals Inc undervalued by DCF analysisJuly 2025 Levels & AI Forecast Swing Trade Picks - baoquankhu1.vn
Why Is Actinium Pharmaceuticals Stock Rising Today? - Stocktwits
Analysis Recap: Can Actinium Pharmaceuticals Inc outperform in the next rallyJuly 2025 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
Is now the right time to enter Actinium Pharmaceuticals Inc.Market Activity Recap & AI Based Buy/Sell Signal Reports - mfd.ru
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting - Yahoo Finance
Performance Recap: Can Actinium Pharmaceuticals Inc outperform in the next rallyJuly 2025 Volume & Verified Stock Trade Ideas - baoquankhu1.vn
ATNM PE Ratio & Valuation, Is ATNM Overvalued - Intellectia AI
Actinium Pharmaceuticals Announces CFO Resignation and New Appointment - TradingView
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):